Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
04/2010
04/06/2010US7691854 Diethyl 2-amino-4-(4-cyanophenyl)-6-methyl-1-(3-methylphenyl)-1,4-dihydro-3,5-pyridine-dicarboxylate; chronic obstructive pulmonary disease, acute coronary syndrome, acute myocardial infarction or development of heart failure
04/06/2010US7691853 Pyrazole compounds useful as protein kinase inhibitors
04/06/2010US7691852 Compounds for enzyme inhibition
04/06/2010US7691851 increased potency and selectivity in relation to currently known MMP-13 inhibitors; treating rheumatoid arthritis, osteoarthritis or inflammation; modified benzoxazine moiety
04/06/2010US7691850 Antibacterial agents
04/06/2010US7691849 Carboxamidine derivatives and their use in the treatment of vascular diseases
04/06/2010US7691848 10-[(2,2'-Dimethyl-1,1'-biphenyl-4-yl)carbonyl]-N-(3-methoxybenzyl)-10,11-dihydro-5H-pyrrolo[2,1-c][1,4]benzodiazepine-3-carboxamide; antifertility agents
04/06/2010US7691847 Method of treating neurological diseases and disorders
04/06/2010US7691846 blood coagulation factor (trypsin-like serine protease enzymes) inhibitor; 1-(3-amino-1,2-benzisoxazol-5-yl)-5-{[5-(2-oxo-1-piperidinyl)-2,3-dihydro-1H-indol-1-yl]carbonyl}-1H-pyrazole-3-carboxamide; anticoagulant; cardiovascular thromboembolic disorder transient ischemic attack, stroke, atherosclerosis
04/06/2010US7691845 Anti-inflammatory agents
04/06/2010US7691844 4-(2-fluorophenylbenzoyl-4-aminobenzoyl)-3'-(2-(N,N-dimethylaminoethylaminocarbonyl))-4-aza-[6,4]-spiro-[5,6]-benzoundec-2'-ene; inner ear disorders, hypertension, congestive heart failure, cardiac insufficiency, coronary vasospasm, cardiac ischemia, liver cirrhosis, renal vasospasm, renal failure
04/06/2010US7691843 Inhibitors of UPD-3-O (R-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase, an enzyme present in gram negative bacteria; azetidine, pyrrolidine, or 3-pyrroline 2-carboxylic acid hydroxyamides; 1-(3,4-dimethoxy-5-propylbenzoyl)pyrrolidine-2R-carboxylic acid hydroxyamide for example
04/06/2010US7691842 Tricyclic 6-alkylidene-penems as β-lactamase inhibitors
04/06/2010US7691841 Azetidine derivatives as CCR-3 receptor antagonist
04/06/2010US7691839 Methods and compositions for blocking platelet and cell adhesion, cell migration and inflammation
04/06/2010US7691838 Method for treating diseases using HSP90-inhibiting agents in combination with antimitotics
04/06/2010US7691837 e.g. 1-{[1,5-bis(4-cholorophenyl)-2-methylpyrrol-3-yl]methyl}-4-(4-fluoro-phenyl)piperazine; Mycobacterium tuberculosis, drug resistant Mycobacterium tuberculosis, Mycobacterium avium-intracellulare complex, Mycobacterium fortuitum or Mycobacterium kansasi
04/06/2010US7691836 Progesterone receptor modulators
04/06/2010US7691835 Therapy for prostate cancer; administering androgen receptor
04/06/2010US7691834 Substance for lowering high cholesterol level in serum and methods for preparing and using the same
04/06/2010US7691833 Administering acetylsalicylic acid and carrier mixtures to prevent tumors
04/06/2010US7691832 Ulcerative colitis and Crohn's disease; 5-aminosalicylic acid or 4-aminosalicylic acid and one or more antioxidants (e.g., N-acetylcysteine)
04/06/2010US7691831 Pharmaceutical combination and method for treatment of reactive arthritis or bursitis
04/06/2010US7691830 compositions containing the sulfate chitinous polymer; interstitial cystitis; cancer in a mucous membrane such as bladder or vaginal cancer; Crohn's disease; inflammatory bowel disease or colitis
04/06/2010US7691829 An aqueous eye drop solution of hydrolyzed collagen to promote and protect tissue and cell growth, reduce scar tissue and repair connective tissues; wound healing agents; bandages; carriers preferably combined with hyaluronic acid or a salt, a polysulfated glycosaminoglycan and/or a glucosamine salt
04/06/2010US7691828 Compositions for ameliorating fecal properties
04/06/2010US7691827 Amide prodrug of gemcitabine, compositions and use thereof
04/06/2010US7691826 Polysialic acid derivatives
04/06/2010US7691825 Adenosine A2B receptor agonists
04/06/2010US7691824 Double-stranded ribonucleic acid (dsRNA), and its use in mediating RNA interference to inhibit the expression of one of the genes of the JC virus and the use of the dsRNA to treat pathological processes mediated by JC virus infection, such as PML; sense, antisense
04/06/2010US7691822 Methods and compositions for treatment of interferon-resistant tumors
04/06/2010US7691820 Administering a 1-(4-thio-beta-D-arabinofuranosyl)- cytosine or 5- or 6-aza compound for inhibiting replication of DNA, immunomodulation and treatment of autoimmune diseases; also claimed is 1-(4-thio- beta -D-arabinofuranosyl)-5-fluorocytosine.
04/06/2010US7691819 Buffer intracellular reduction and oxidation for the stressed cells in various disease states; beneficial as adjunctive support therapy, multiple chemical sensitivity syndrome, Charcot-Marie-Tooth disease, Dejerine-Sottas syndrome, Roussy-Levy syndrome, Rosenberg Chutorian syndrome, Korsakoff syndrome
04/06/2010US7691818 Identified new isostere of the dipeptide phenylalanine-proline (Phe-Pro) having four stereogenic centers on which compounds are based; enzyme inhibitors; viricides; HIV; post-exposure prophylaxis and as infection therapy
04/06/2010US7691811 Enhancing the activity and/or duration of action of soft anti-inflammatory steroids such as loteprednol etabonate with a synergistic amount of another steroid such as cortisone
04/06/2010US7691635 Such as heat resistant diazomethyl compounds; kits for solid phase nucleic acid synthesis
04/06/2010US7691632 Kit for detecting the level of cyclin-dependent kinase inhibitor P16 gene expression
04/06/2010US7691630 composition for foliar application to plants comprising a plant systemic inducer and a reactive oxygen species wherein the amount of reactive oxygen species is sufficient to increase the level of a natural plant product; for improving plant quality and yield in the presence of pathogens
04/06/2010US7691606 Soluble GDNFR (Glial-cell Derived Neurotrophic Factor) that retains both ligand binding, and receptor signaling function (via Ret receptor tyrosine kinase) used to impart, restore, or enhance GDNFR alpha -ligand (preferably GDNF) responsiveness to cells; kidney diseases
04/06/2010US7691593 Regulation of lung tissue by patched therapeutics and formulations and uses related thereto
04/06/2010US7691591 Methods of identifying and isolating cells expressing DC-sign
04/06/2010US7691563 Method for alleviating pain using sphingosine-1-phosphate and related compounds, and assays for identifying such compounds
04/06/2010US7691425 Method for manufacturing α-glycosylisoquercitrin, intermediate product and by-product thereof
04/06/2010US7691420 comprising a catechin as found in green tea, e.g., epigallocatechin gallate, and ligand which activates the peroxisome proliferatoractivated receptor gamma
04/06/2010US7691419 topical composition for treating skin diseases comprises calendula, tea tree oil, eucalyptus oil, grape seed oil, and Aloe vera; composition may also include beeswax, vegetable oil, vitamin E, rosemary oil, or shea butter or combinations thereof to further enhance its beneficial effects
04/06/2010US7691411 Pharmaceutical formulae for thyroid hormones and procedures for obtaining them
04/06/2010US7691409 Simethicone solid oral dosage form
04/06/2010US7691406 Zeaxanthin formulations for human ingestion
04/06/2010US7691404 Acrylate adhesive, a polyvinylpyrrolidone having a molecular weight of 1,000,000-5,000,000; a polyvinylpyrrolidone having a molecular weight of 2,000-50,000; a non-ionic surfactant; a terpene; and a dissolution assistant.
04/06/2010US7691403 Grampositive bactericide using cerulenin, triclosan, chloroprene
04/06/2010US7691392 Method of treating multiple myeloma using 17-AAG or 17-AG or a prodrug of either
04/06/2010US7691378 Treating carcinomas or adenocarcinomas using at least one anti-TNF (tumor necrosis factor) antibody
04/06/2010US7691377 Administering glutamate release inhibitor and glutamate receptor antagonist; antiapoptosis
04/06/2010US7691364 Functionalized drugs and polymers derived therefrom
04/06/2010US7691358 water solubilizer for nanocarbons contains a surfactant which can form a spherical micelle vesicle having a diameter of 50-2,000 nm in a water solution or a water-soluble polymer having a weight-average molecular weight of 10,000-50,000,000 as an active constituent
04/06/2010US7691297 Process for the manufacture of powderous preparations of fat-soluble substances
04/06/2010CA2566108C Proline derivatives and their use as dipeptidyl peptidase iv inhibitors
04/06/2010CA2546192C Pyrrolopyrimidine compounds useful in treatment of cancer
04/06/2010CA2536638C Solid pharmaceutical dosage form
04/06/2010CA2513738C Casr antagonist
04/06/2010CA2496712C New process for synthesizing derivatives of 1,3,4,5-tetrahydro-2h-3-benzazepin-2-one and its application to the synthesis of ivabradine and its pharmaceutically acceptable acid addition salts
04/06/2010CA2475137C New heterocyclic oxime derivatives, their preparation process and the pharmaceutical compositions that contain them
04/06/2010CA2464846C Dibenzylamine compounds and pharmaceutical use thereof
04/06/2010CA2459009C Novel piperidin-2,6-dione bisulphate salts and their use for the treatment of stress-related affective disorders
04/06/2010CA2455181C Benzimidazo[4,5-f]isoquinolinone derivatives
04/06/2010CA2453383C Piperidine derivatives as nmda receptor antagonists
04/06/2010CA2449899C Piperazinylpyrazines compounds as antagonists of serotonin 5-ht2 receptor
04/06/2010CA2445346C N-substituted pyrazole-o-glycoside derivatives and therapeutic agent for diabetes containing the same
04/06/2010CA2416220C Preparation of phosphatase inhibitors
04/06/2010CA2397636C Dihydro-1,3,5-triazine amine derivatives and their therapeutic uses
04/06/2010CA2386017C Drug delivery of phase changing formulation
04/06/2010CA2375361C An antimicrobial composition
04/06/2010CA2361057C Quinoline derivatives and quinazoline derivatives
04/06/2010CA2358505C Novel hydrogel isolated cochleate formulations, process of preparation and their use for the delivery of biologically relevant molecules
04/06/2010CA2351709C Novel triazolo(4,5-d)pyrimidine compounds
04/06/2010CA2339182C Improvement of cardiac function by mesenchymal stem cell transplantation
04/06/2010CA2319807C Novel antifungal compound and process for producing the same
04/06/2010CA2309195C Stable ascorbic acid preparation for topical use
04/06/2010CA2258675C 2-cyclopenten-1-one as an inducer of hsp70
04/06/2010CA2252466C Hepatitis b monoclonal antibodies
04/02/2010CA2678320A1 Transdermal drug delivery system for liquid active ingredient
04/01/2010WO2010037129A1 Quinazolinone, quinolone and related analogs as sirtuin modulators
04/01/2010WO2010037127A1 Chromenone analogs as sirtuin modulators
04/01/2010WO2010037122A1 Combinations of a rate control agent and an a-2-alpha receptor antagonist for use in multidetector computed tomography methods
04/01/2010WO2010037095A2 Agents and methods for the treatment of cancer
04/01/2010WO2010037081A1 Melanocortin receptor-specific spiro-piperidine compounds
04/01/2010WO2010037067A1 Fused ring thiophene dyes for imaging and therapy
04/01/2010WO2010037066A2 Dosage units of 3-(6-(1-(2,2-difluorobenzo [d] [1,3] dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
04/01/2010WO2010037059A2 Heteroaryl antagonists of prostaglandin d2 receptors
04/01/2010WO2010037054A2 Heteroaryl antagonists of prostaglandin d2 receptors
04/01/2010WO2010037050A2 Synthesis of functionalized octahydro-isoquinolin-1-one-8-carboxamides, octahydro-isoquinolin-1-one-8-carboxylic esters and analogs, and therapeutic methods
04/01/2010WO2010037044A1 Bioadhesive constructs
04/01/2010WO2010036998A2 Indole and indoline derivatives and methods of use thereof
04/01/2010WO2010036977A2 Combination therapies with topiramate for seizures, restless legs syndrome, and other neurological conditions
04/01/2010WO2010036973A1 Treatment of hyperproliferative disorders using cardiac glycosides
04/01/2010WO2010036962A1 Lipid formulated compositions and methods for inhibiting expression of serum amyloid a gene
04/01/2010WO2010036958A1 Methods of treatment for mrsa infections
04/01/2010WO2010036947A2 Lipid based pharmaceutical preparations for oral and topical application; their compositions, methods, and uses thereof
04/01/2010WO2010036945A2 Nanoemulsion therapeutic compositions and methods of using the same
04/01/2010WO2010036937A1 Topical formulations for treatment of neuropathy